RxDoctor Payments Data

Adam Albano, MD

Internal Medicine · Marietta, GANPI 1154818102

Payments from drug & device makers

$1,675in general payments, 2019–2025

Across 91 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$496
  • AbbVie$155
  • GSK$134
  • Astellas Pharma US Inc$124
  • Inspire Medical Systems, Inc.$101
  • Abbott$97
  • plus $569 from 19 others

What the payments were for

  • Food & beverage$1,675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,675 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$148,025
Medicare patients
645
Services billed
4,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide204$221,332
JardianceEmpagliflozin110$135,751
OzempicSemaglutide114$120,201
EliquisApixaban107$107,609
TrulicityDulaglutide75$75,204
FarxigaDapagliflozin Propanediol35$37,810
JanuviaSitagliptin Phosphate29$37,666
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,939
XareltoRivaroxaban12$18,411
RybelsusSemaglutide15$16,775
MyrbetriqMirabegron12$16,684
LinzessLinaclotide19$15,409
Fiasp FlextouchInsulin Aspart (Niacinamide)20$13,049
Atorvastatin Calcium792$7,251
Tresiba Flextouch U-100Insulin Degludec14$6,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$496$136,975129 claims
Boehringer IngelheimJardiance$26$135,751110 claims
PfizerEliquis$53$107,609107 claims
GSKTrelegy Ellipta, Anoro Ellipta$134$27,51439 claims
AbbVieLinzess, Synthroid$155$17,58758 claims
Astellas Pharma US IncMyrbetriq$124$16,68412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →